The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close. Penumbra shareholders can elect to receive either $374 in cash, or ​3.8721 Boston Scientific shares, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback